Salvinal, a Novel Microtubule Inhibitor Isolated from Salvia miltiorrhizae Bunge (Danshen), with Antimitotic Activity in Multidrug-Sensitive and -Resistant Human Tumor Cells

Molecular Pharmacology

Volumn 65, Issue 1, 2004, Pages 77-84

  Chang, Jang Yang ^a,c   Chang, Chi Yen ^a   Kuo, Ching Chuan ^a   Chen, Li Tzong ^a   Wein, Yung Shung ^b   Kuo, Yueh Hsiung ^b  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; ANTIMITOTIC AGENT; CASPASE 3; CELL CYCLE PROTEIN; CELL CYCLE PROTEIN 25C; COLCHICINE; CYCLIN B1; DNA FRAGMENT; ETOPOSIDE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; PROTEIN BCL 2; PROTEIN KINASE; SALVINAL; UNCLASSIFIED DRUG; VINCRISTINE;

APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CELL STRAIN DBTRG; CELL STRAIN H460; CELL STRAIN HEPG2; CELL STRAIN HONE 1; CELL STRAIN HT29; CELL STRAIN KB; CELL STRAIN MCF 7; CELL STRAIN TSGH; COLON CARCINOMA; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG SYNTHESIS; FLOW CYTOMETRY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MICROTUBULE ASSEMBLY; MITOSIS; MOUTH CARCINOMA; MULTIDRUG RESISTANCE; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SALVIA MILTIORRHIZA; SOLID TUMOR; STOMACH CARCINOMA; TUMOR CELL LINE;

ALDEHYDES; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOFURANS; CELL DIVISION; DRUG RESISTANCE, MULTIPLE; DRUG SCREENING ASSAYS, ANTITUMOR; DRUGS, CHINESE HERBAL; G2 PHASE; HUMANS; KB CELLS; MICROTUBULES; MITOSIS; PHENANTHROLINES; PROTO-ONCOGENE PROTEINS C-BCL-2; SALVIA MILTIORRHIZA; TUBULIN MODULATORS; TUMOR CELLS, CULTURED;

EID: 1642495631     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.65.1.77     Document Type: Article

References (40)

1. Blagosklonny MV, Giannakakou P, el Deiry WS, Kingston DG, Higgs PI, Neckers L, and Fojo T (1997) Raf-1/Bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res 57:130-135.
2. Blagosklonny MV, Schulte TW, Nguyen P, Mimnaugh EG, Trepel J, and Neckers L (1995) Taxol induction of P21WAF1 and P53 requires C-Raf-1. Cancer Res 55:4623-4626.
3. Chang HM and But PP (1986) Pharmacology and Applications of Chinese Material Medica, World Scientific Publication, Singapore.
4. Davis FM, Tsao TY, Fowler SK, and Rao PN (1983) Monoclonal antibodies to mitotic cells. Proc Natl Acad Sci USA 80:2926-2930.
5. Decaudin D, Geley S, Hirsch T, Castedo M, Marchetti P, Macho A, Kofler R, and Kroemer G (1997) Bcl-2 and Bcl-XL antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents. Cancer Res 57:62-67.
6. Draetta GF (1997) Cell cycle: will the real Cdk-activating kinase please stand up. Curr Biol 7:R50-R52.
7. Dumontet C and Sikic BI (1999) Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport and cell death. J Clin Oncol 17:1061-1070.
8. Ferguson PJ, Fisher MH, Stephenson J, Li DH, Zhou BS, and Cheng YC (1988) Combined modalities of resistance in etoposide-resistant human KB cell lines. Cancer Res 48:5956-5964.
9. Finlay GJ, Baguley BC, and Wilson WR (1984) A semiautomated microculture method for investigating growth inhibitory effects of cytotoxic compounds on exponentially growing carcinoma cells. Anal Biochem 139:272-277.
10. Germann UA (1996) P-Glycoprotein-a mediator of multidrug resistance in tumour cells. Eur J Cancer 32A:927-944.
11. Haldar S, Jena N, and Croce CM (1995) Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA 92:4507-4511.
12. Hamel E (1996) Antimitotic natural products and their interactions with tubulin. Med Res Rev 16:207-231.
13. Heald R, McLoughlin M, and Mckeon F (1993) Human Weel maintains mitotic timing by protecting the nucleus from cytoplasmically activated Cdc2 kinase. Cell 74:463-474.
14. Hoffmann I, Clarke PR, Marcote MJ, Karsenti E, and Draetta G (1993) Phosphorylation and activation of human Cdc25-C by Cdc2-cyclin B and its involvement in the self-amplification of MPF at mitosis. EMBO (Eur Mol Biol Organ) J 12:53-63.
15. Jiang JD, Wang Y, Roboz J, Strauchen J, Holland JF, and Bekesi JG (1998) Inhibition of microtubule assembly in tumor cells by 3-bromoacetylamino benzoylurea, a new cancericidal compound. Cancer Res 58:2126-2133.
16. Jordan A, Hadfield JA, Lawrence NJ, and McGown AT (1998) Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med Res Rev 18:259-296.
17. Kavallaris M, Kuo DY, Burkhart CA, Regl DL, Norris MD, Haber M, and Horwitz SB (1997) Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Investig 100:1282-1293.
18. Kavallaris M, Tait AS, Walsh BJ, He L, Horwitz SB, Norris MD, and Haber M (2001) Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells. Cancer Res 61:5803-5809.
19. Korsmeyer SJ (1995) Regulators of cell death. Trends Genet 11:101-105.
20. Kumagai A and Dunphy WG (1991) The Cdc25 protein controls tyrosine dephosphorylation of the Cdc2 protein in a cell-free system. Cell 64:903-914.
21. Kuo Y-H and Wu C-H (1996) Synthesis of 5-(3-hydroxypropyl)-7-methoxy-2-(3′-methoxy-4′-hydroxyphenyl) -3-benzo[b]furancarbaldehyde, a novel adenosine A1 receptor ligand from the root of Salvia miltiorrhizae. J Nat Prod (Lloydia) 59:625-628.
22. Lin H-C, Ding H-Y, and Chang W-L (2001) Two new fatty diterpenoids from Salvia miltiorrhizae. J Nat Prod (Lloydia) 64:648-650.
23. Liu GT, Zhang TM, Wang BE, and Wang YW (1992) Protective action of seven natural phenolic compounds against peroxidative damage to biomembranes. Biochem Pharmacol 43:147-152.
24. Paull KD, Lin CM, Malspeis L, and Hamel E (1992) Identification of novel antimitotic agents acting at the tubulin level by computer-assisted evaluation of differential cytotoxicity data. Cancer Res 52:3892-3900.
25. Ramachandran C and Melnick SJ (1999) Multidrug resistance in human tumors-molecular diagnosis and clinical significance. Mol Diagn 4:81-94.
26. Ranganathan S, Dexter DW, Benetatos CA, Chapman AE, Tew KD, and Hudes GR (1996) Increase of beta(III)- and beta(IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance. Cancer Res 56:2584-2589.
27. Rowinsky EK, Cazenave LA, and Donehower RC (1990) Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 82:1247-1259.
28. Rowinsky EK and Donehower RC (1991) The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmacol Ther 52:35-84.
29. Russo AA, Jeffrey PD, and Pavletich NP (1996) Structural basis of cyclin-dependent kinase activation by phosphorylation. Nat Struct Biol 3:696-700.
30. Scammells PJ, Baker SP, and Beauglehole AR (1998) XH-14 analogues as adenosine antagonists. Bioorg Med Chem 6:1517-1524.
31. Scatena CD, Stewart ZA, Mays D, Tang LJ, Keefer CJ, Leach SD, and Pietenpol JA (1998) Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and taxol-induced growth arrest. J Biol Chem 273:30777-30784.
32. Schiff PB and Horwitz SB (1980) Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77:1561-1565.
33. Strausfeld U, Labbe JC, Fesquet D, Cavadore JC, Picard A, Sadhu K, Russell P, and Doree M (1991) Dephosphorylation and activation of a P34cdc2/cyclin B complex in vitro by human CDC25 protein. Nature (Lond) 351:242-245.
34. Tahir SK, Han EK, Credo B, Jae HS, Pietenpol JA, Scatena CD, Wu-Wong JR, Frost D, Sham H, Rosenberg SH, et al. (2001) A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors. Cancer Res 61:5480-5485.
35. Westendorf JM, Rao PN, and Gerace L (1994) Cloning of CDNAs for M-phase phosphoproteins recognized by the MPM2 monoclonal antibody and determination of the phosphorylated epitope. Proc Natl Acad Sci USA 91:714-718.
36. Wittmann T, Hyman A, and Desai A (2001) The spindle: a dynamic assembly of microtubules and motors. Nat Cell Biol 3:E28-E34.
37. Wu WL, Chang WL, and Chen CF (1991) Cytotoxic activities of tanshinones against human carcinoma cell lines. Am J Chin Med 19:207-216.
38. Yagi A, Fujimoto K, Tanonaka K, Hirai K, and Takeo S (1989) Possible active components of tan-shen (Salvia miltiorrhiza) for protection of the myocardium against ischemia-induced derangements. Planta Med 55:51-54.
39. 1 receptor ligand isolated from Salvia miltiorrhiza bunge (Danshen). Tetrahedron Lett 32: 2061-2064.
40. Yang Z, Liu HB, Lee CM, Chang HM, and Wong HNC (1992) Compounds From Danshen. Part 7. Regioselective introduction of carbon-3 substituents to 5-alkyl-7-methoxy-2-phenylbenzo[b]furans: synthesis of a novel adenosine Al receptor ligand and its derivatives. J Org Chem 57:7248-7257.